M&A / Deals

Ionis grants Recordati rights to zilganersen for Alexander disease

Pharmaceutical Technology

Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.

Rare Disease

Read full story

pharminent June 26, 2026 (Last updated: June 26, 2026)

Pharmaceutical Technology

Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.

Rare Disease

Read full story

Related Stories

Immunai and Boehringer partner to identify T-cell targets

Merck buys life sciences firm Bio-Techne in $11.3bn deal

URA and Lilly join forces to harmonise drug-wearable obesity care

You May Have Missed

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

Replimune gets early August decision date for twice-rejected melanoma drug

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

Immunai and Boehringer partner to identify T-cell targets